论文信息 - Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD. - 字舞流文

Efficacy and safety of the PCSK9 inhibitor alirocumab 300 mg every 4 weeks in patients with ASCVD.

D. Rader | J. Bergeron | P. Moriarty | G. Langslet | M. Baccara-Dinet | G. Manvelian | E. Roth | Jian Zhao